On October 19, 2023 Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, reported e-poster presentations at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting, taking place November 5-7, 2023, in Seoul, Korea (Press release, Aadi Bioscience, OCT 19, 2023, View Source [SID1234636156]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract and e-poster presentation details are below:
Title: "A phase 2, open-label, single-arm, prospective, multi-center study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer"
Session Title: e-poster
Date/Time: November 5-7, 2023
Authors: Lauren E. Dockery, MD, MS; Anna Priebe, MD; Linda Duska, MD, MPH; Angela K. Green, MD; Cara Mathews, MD; Fernanda Musa, MD; David O’Malley, MD; Allison Puechl, MD; Li Ding, MS, MA; Anita N. Schmid, PhD; Willis H. Navarro, MD; Brian Slomovitz, MD; Kathleen Moore, MD
Abstract highlights:
This is a Phase 2 open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus and letrozole in patients with advanced or recurrent endometrioid endometrial carcinoma, exploring the potential for this combination to produce additive anti-tumor activity in patients with endometrioid-type endometrial carcinoma (EEC)
Dysregulation of mTOR signaling is implicated in the pathology of EEC, in which >80% harbor PTEN or PI3K/AKT/mTOR pathway alterations
Prior clinical studies with mTOR inhibitors and letrozole in endometrial cancer patients have yielded promising results
Alternative treatment options for advanced or recurrent endometrioid-type endometrial carcinoma (EEC) remain necessary despite recent pivotal data demonstrating improved outcomes with immunotherapy plus chemotherapy
In preclinical models, intravenous nab-sirolimus demonstrates significantly higher tumor growth inhibition, intra-tumoral drug accumulation, and greater mTOR target suppression compared with oral inhibitors
An encore presentation titled, "Phase 2, Multicenter, Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION1)" will be displayed as an e-poster during the meeting.
More information can be found on the IGCS meeting website.